Analysts at HC Wainwright decreased their FY2025 earnings per share (EPS) estimates for shares of Syndax Pharmaceuticals in a ...

HC Wainwright restated their buy rating on shares of Syndax Pharmaceuticals (NASDAQ:SNDX – Free Report) in a report published ...

Highlights,Target price adjustments for Syndax Pharmaceuticals reflect varied market sentiment.,Executive decisions on stock ...

About Syndax Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj ® ...

Syndax Pharmaceuticals Inc (SNDX) reports promising revenue from Revv Forge launch and outlines strategic growth plans, ...

Kura Oncology's (KURA) ziftomenib shows AML promise amid competition. See why I'm inclined to view the current price levels ...

Q4 2024 Earnings Call Transcript March 3, 2025 Operator: Good day, everyone, and welcome to the Syndax Fourth Quarter and Full Year 2024 Earnings Conference Call. Today’s call is being recorded.

Scotiabank analyst George Farmer maintained a Hold rating on Syndax Pharmaceuticals (SNDX – Research Report) today and set a price target of ...

Syndax Pharmaceuticals Inc. ( ($SNDX) ) has released its Q4 earnings. Here is a breakdown of the information Syndax Pharmaceuticals Inc. presented ...

Explore Syndax Pharmaceuticals' Q4 2024 earnings highlights, including strong Revuforj launch revenue, label expansion plans, and a $2 billion ...

Syndax (SNDX) delivered earnings and revenue surprises of -1.85% and 65.45%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

The results fell short of Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of $1.08 per share. The biopharmaceutical company posted ...